Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT05748145

Metronidazole as Preoperative Therapy in CRC / FusoMetro-001

Led by Oncology Institute of Southern Switzerland · Updated on 2025-11-18

40

Participants Needed

1

Research Sites

172 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The proposed proof-of concept trial aims at determining the effectiveness of metronidazole in decreasing the Fusobacterium nucleatum load in tissues and possibly on its detrimental effects on tumor cells and tumor microenvironment.

CONDITIONS

Official Title

Metronidazole as Preoperative Therapy in CRC / FusoMetro-001

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Provided written informed consent according to ICH/GCP regulations before registration
  • Age 18 years or older
  • Untreated, primary colorectal adenocarcinoma located more than 15 cm from the anal verge
  • Colonoscopy with endoscopic biopsy confirming disease
  • Scheduled for surgical tumor removal before any other therapy
Not Eligible

You will not qualify if you...

  • Insufficient biopsy material for further evaluation
  • Known allergy to metronidazole or nitroimidazole derivatives
  • Use of oral or parenteral antibiotics within 6 weeks before enrollment
  • Emergency surgery planned within less than 14 days before treatment start
  • Other cancer within 5 years except certain skin cancers and cervical carcinoma in situ
  • Previous anticancer treatment before surgery
  • Pregnant or breastfeeding women
  • Fertile patients not using safe contraception during the study
  • Significant other diseases such as kidney, liver, or heart problems
  • Inability to consent or follow study procedures due to language or psychological issues
  • Participation in another drug trial within 30 days before or during this study
  • Any serious medical, psychiatric, familial, or geographical condition interfering with treatment or compliance

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Oncology Institute of Southern Switzerland

Bellinzona, Canton Ticino, Switzerland, 6500

Actively Recruiting

Loading map...

Research Team

S

Sara De Dosso, MD

CONTACT

L

Luigi Tortola, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here